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Summary
Prostate cancer patients frequently experience resistance to androgen deprivation therapy (ADT). 
Acquiring a better understanding of the mechanisms controlling the development of castration 
resistant prostate cancer (CRPC) remains an unmet clinical need. The well-established dependency 
of cancer cells on the tumor microenvironment suggests that it might control the emergence of 
CRPC. Here, we identify IL23 produced by myeloid-derived suppressor cells (MDSCs) as a driver 
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of CRPC. Mechanistically, IL23 secreted by MDSCs can activate the androgen receptor pathway 
in prostate tumor cells, promoting cell survival and proliferation in androgen deprived conditions. 
Intra-tumor MDSC infiltration, and IL23 concentration, increases in the blood and tumor samples 
of CRPC patients. Antibody-mediated inactivation of IL23 restored sensitivity to ADT in mice. 
Taken together, these results reveal that MDSCs promote CRPC by acting in a non-cell 
autonomous manner. Treatments that block IL23 can oppose MDSC-mediated castration resistance 
and synergize with standard of care therapies.
Prostate cancer is the most commonly diagnosed male cancer in the world and the second 
leading cause of male cancer mortality1. After the identification that androgens and AR 
signaling promote prostate cancer progression, ADT has become the mainstay of prostate 
cancer therapy for patients at different stages of disease2. However, a significant fraction of 
patients receiving such treatments ultimately progress, developing CRPC2. The prognosis of 
CRPC patients remains poor and the treatment of these patients remains a major unmet 
medical need2–8. A better understanding of the mechanisms that drive CRPC could identify 
more effective therapies. Deregulated AR signaling, induced by genomic amplification of 
the AR locus, AR splice variants and activation of co-regulators of the AR, is considered the 
major determinant of CRPC2. Activation of several AR-alternative signaling pathways also 
promotes CRPC9,10. However, these mechanisms imply cell-autonomous alterations 
occurring in prostate tumor cells and do not take in consideration that these cells are 
surrounded by a complex tumor microenvironment. The well-established dependency of 
cancer cells on the tumor microenvironment11 suggests that the non-cancer-cell component 
of the tumor may control prostate cancer progression, although the contribution of the tumor 
microenvironment, and in particular of the tumor immune response to the emergence of 
CRPC, remains elusive12,13. We and others have previously reported that MDSCs are a 
prominent immune cell subset infiltrating the CRPC microenvironment14–16. MDSCs are a 
heterogeneous population of activated immune cells expanded in pathological conditions, 
including cancer, with potent immunosuppressing activity17. Based on their expression 
markers, MDSCs can be classified into monocytic (Mo)-MDSCs or polymorphonuclear 
(PMN)-MDSCs18. Higher numbers of circulating and tumor-infiltrating MDSCs have been 
observed in a large fraction of patients suffering from different tumors including prostate 
cancer17,19,20. MDSCs can support tumorigenesis by either suppressing the antitumor 
immune response or by promoting angiogenesis and senescence evasion in a number of 
contexts including prostate cancer15,16,21. MDSCs have been also found elevated in 
patients that do not respond to ADT20. However, whether MDSCs support androgen-
independent tumor growth and the emergence of CRPC remains unknown. Here, we show 
that IL23 secreted by increased numbers of MDSCs in both human and mouse prostate 
tumors can confer androgen independence in a non-cell autonomous manner through the 
activation of AR signaling. Inhibition of IL23 or IL23 receptor signaling in these tumors 
restores sensitivity to ADT.
MDSCs confer castration resistance
By analyzing castration-sensitive (CSPC) and CRPC biopsies we found that PMN-MDSCs 
(CD11b+ CD33+ CD15+ cells)18 were enriched in CRPC and localized in close proximity to 
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EpCAM+ epithelial tumor cells (Figure 1a; Extended Data 1a). Interestingly, increased 
PMN-MDSCs in tumors were not associated with elevated levels of CD11b+ CD15- cells 
(Extended Data 1b). These findings prompted us to hypothesize that tumor infiltrating PMN-
MDSCs could directly contribute to the emergence of CRPC. We investigated this 
hypothesis by using the Pten null prostate conditional (Ptenpc-/-) mouse model and two 
additional allograft models of prostate cancer (TRAMP-C1 and MyC-CaP) that develop 
tumors driven by Pten loss, p53/RB inactivation or c-MYC amplification respectively2. As 
previously reported22, surgical castration in Ptenpc-/- mice leads to initial tumor regression 
(castration sensitive (CS) phase, t=4) followed by tumor progression and emergence of 
castration resistant prostate tumors (castration resistant (CR) phase, t=12) (Figure 1b; 
Extended Data 1c-d), with AR target genes being down-regulated in tumors in the CS phase 
and up-regulated in the CR phase when compared with sham-operated mice (Figure 1c). To 
assess whether castration affects the recruitment of PMN-MDSCs in these tumors, we 
measured the frequency of PMN-MDSCs (CD11b+ Ly6Gbright Ly6Clow cells)18 in sham-
operated and castrated Ptenpc-/- mice in a time course experiment. Interestingly, PMN-
MDSCs number increased over time, paralleling the emergence of CRPC (Figure 1b, d; 
Extended Data 1e; Extended Data 2a). Of note, PMN-MDSCs represented the major 
immune subset that increased in Pten null tumors upon castration (Figure 1e; Extended Data 
2b-c). This increase in PMN-MDSCs was validated in TRAMP-C1 and MyC-CaP castrated 
mice that develop CRPC within 10-days after castration (Extended Data 1f-i; Extended Data 
2a). Intriguingly, while PMN-MDSCs increased in castrated tumors, the frequency of tumor-
infiltrating macrophages (TAMs) decreased (Figure 1e; Extended Data 2c).
To assess whether factors secreted by MDSCs impact AR pathway signaling in prostate 
cancer cells, we co-cultured two murine androgen-dependent prostate cancer cell lines, 
TRAMP-C1 and MyC-CaP, in the presence of conditioned medium (C. M.) obtained from 
bone marrow (BM)-derived MDSCs (Figure 1f, Extended Data 3a-b). Surprisingly, the C. 
M. of MDSCs sustained the proliferation and survival of cells cultured under full androgen 
deprivation (F. A. D.), enhancing the transcription of AR target genes (Figure 1g-j, Extended 
Data 3c-f). These results were further validated in both androgen-dependent (LNCaP and 
VCaP) and androgen-independent (22Rv1 and PC3) human prostate cancer cell lines 
cultured in presence of C. M. from human BM-MDSCs (Figure 1k-l; Extended Data 3g-i). 
Taken together, these data demonstrated that MDSCs can regulate, in a paracrine manner, 
androgen deprivation sensitivity in prostate tumor cells. We next assessed whether depletion 
of MDSCs could delay the emergence of CRPC in castrated mice. We therefore treated 
castrated Ptenpc-/- mice, TRAMP-C1 and MyC-CaP allograft mice with AZD5069, a 
selective CXCR2 antagonist (αCXCR2) under clinical evaluation23. Treatment with 
αCXCR2 strongly reduced the tumor infiltration of PMN-MDSCs in all the mouse models 
analyzed (Extended Data 3j; Extended Data 4a,e). Notably, while Ptenpc-/- castrated mice 
treated with αCXCR2 did not progress to CRPCs, untreated mice developed CRPCs four 
months after castration as demonstrated by the levels of AR target genes (Figure 1m-n). This 
finding was also confirmed in TRAMP-C1 and MyC-CaP allograft mice, where inhibition of 
MDSCs tumor recruitment delayed the emergence of CRPC as shown by decreased tumor 
size and level of AR target genes in treated mice, resulting in longer survival in αCXCR2 
treated mice (Extended Data 4a-h). Of note, αCXCR2 treatment did not directly impact cell 
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proliferation and AR activity in mouse prostate tumor cells cultured in F. A. D., in vitro 
(Extended Data 3k-l). To corroborate the role of MDSCs as drivers of CRPC in the human 
setting, we co-injected hBM-MDSCs with LNCaP cells in NOD-SCID mice, and assessed 
tumor growth over time in intact versus castrated hosts. In line with our previous evidence, 
the co-injection of LNCaP with hBM-MDSCs conferred resistance to castration (Extended 
Data 4i-j). Taken together, these data indicated that MDSCs are increased in CRPC and can 
promote prostate tumor cell proliferation by sustaining AR signaling following androgen 
deprivation.
IL23 drives insensitivity to androgen deprivation
To determine which MDSC-secreted factors drive castration resistance, we performed a 
NanoString nCounter gene expression assay in Ptenpc-/- tumors from sham and castrated 
mice. IL23 and one of the subunits of IL23 receptor (IL12Rβ1) were the most up-regulated 
genes in tumors from castrate mice when compared to controls (Extended Data 5a). Of note, 
factors previously linked to the regulation of AR pathway such as IL6 were not up-regulated 
in Ptenpc-/- tumors after castration (Extended Data 5a) 13. In line with this evidence, 
cytokine profile analysis in C. M. from murine MDSCs showed that IL23 was the most over-
expressed factor produced by these cells (Extended Data 5b). Immunofluorescence and flow 
cytometry analyses further confirmed that tumor-infiltrating MDSCs expressed IL23 in vivo, 
with PMN-MDSCs infiltrating castration-resistant tumors expressing even higher levels of 
IL23 when compared to treatment-naïve tumors (Figure 2a-b). Moreover, as found in mice, 
PMN-MDSCs infiltrating tumor biopsies from CRPC patients expressed IL23 (Figure 2d-e; 
Extended Data 6a) with the frequency of IL23-producing tumor-infiltrating PMN-MDSCs 
being higher in CRPC biopsies than in CSPC biopsies (Figure 2e). Notably, expression of 
CXCL5, a chemokine that stimulates chemotaxis of myeloid cells through CXCR224, was 
strongly up-regulated in castrated tumors compared to controls (Extended Data 5a, c-d). 
This, together with the previous finding that CXCR2 inhibition efficiently decreases the 
recruitment of MDSCs in castrated mice, implicates this factor as a major regulator of 
MDSC recruitment in CRPC.
We next assessed the levels of IL23 receptor (IL23R) in sham and castrated Ptenpc-/- tumors, 
and found that IL23R levels increased in tumor cells following castration (Figure 2c). This 
was further validated in TRAMP-C1 cells cultured in androgen deprived conditions in vitro 
(Extended Data 5e-f). Furthermore, plasma IL23 levels in CRPC patients were substantially 
higher than in CSPC patients (Figure 2f; Extended Data 5g) and statistically correlated with 
tumor-infiltrating PMN-MDSC counts (EpCAM- CD11b+ CD33+ CD15+; Figure 2g) but not 
with other myeloid cell population counts (CD11b+ CD15-; Extended Data 6b). Overall, 
these data demonstrated that IL23 is elevated in both mouse and human CRPCs, with IL23 
levels correlating with the number of tumor-infiltrating PMN-MDSCs. Overall, tumor 
biopsies from CRPC patients also had much higher IL23 and IL23R mRNA levels than 
treatment-naïve patients (Extended Data 6c-d) with IL23 mRNA levels being associated 
with MDSC associated mRNA in CRPC biopsies (Extended Data 6e-f).
In line with this evidence, the primary source of IL23 in castrated Ptenpc-/- tumors was 
ascribed to be PMN-MDSCs (Extended Data 6g). Note that TAMs and epithelial tumor cells 
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were only a small fraction of the total IL23 positive cells in these tumors (Extended Data 
6g). In keeping with this, IL23 levels significantly decreased in castrated Ptenpc-/- tumors 
depleted of MDSCs (Extended Data 6h), while depletion of TAMs by an αCSF1R 
antibody25 in mice harbouring TRAMP-C1 did not delay the emergence of CRPC. 
Conversely, the reduction of PMN-MDSCs by an αCXCR2 antagonist robustly delayed the 
emergence of CRPC (Figure 2h-i; Extended Data 6i). Overall, therefore, IL23 levels 
significantly decreased in tumors depleted of MDSCs but not of TAMs (Extended Data 6j).
To functionally validate these findings, we cultured prostate tumor cells in the presence of 
C.M. of BM-MDSCs from IL23 wild type (C.M. BM-MDSCsIL23wt) or IL23 knockout mice 
(C.M. BM-MDSCsIL23ko). The C.M. of BM-MDSCsIL23wt, as well as treatment with 
recombinant IL23, promoted the proliferation, survival and increased transcription of 
androgen receptor target genes in prostate cancer cells kept in F. A. D.; conversely, the C.M. 
of BM-MDSCsIL23ko was ineffective in impacting these (Figure 2j-m). Of note, deleting 
IL23 in BM-MDSCs did not impact the levels of other secreted factors in these cells 
(Extended Data 7a). Indeed, BM-MDSCsIL23wt and BM-MDSCsIL23ko cells had equal 
immunosuppressive capability (Extended Data 7b). These results were further validated in a 
subset of androgen-dependent organoids derived from patient-derived xenografts (PDX) and 
LNCaP cells respectively kept in F.A.D and treated in the presence or absence of human 
recombinant IL23 (Figure 2n). Taken together, these findings identify IL23 as an MDSC-
secreted factor that can sustain prostate cancer cell proliferation and survival as well as the 
transcription of AR driven target genes in prostate cancer cells cultured in F.A.D.
MDSCs activate the IL23/RORγ pathway
To determine whether MDSC-derived IL23 promotes the emergence of castration resistance 
in vivo, we next reconstituted lethally irradiated sham-operated or castrated-Ptenpc-/- mice 
with BM precursors from IL23wt or IL23ko mice (yielding Ptenpc-/-; IL23wt mice and 
Ptenpc-/-; IL23ko mice) (Extended Data 8a). Mice were reconstituted with BM deprived of T, 
B and NK cells (Extended Data 8b). The absence of IL23 in the myeloid compartment led to 
a dramatic reduction in prostate cancer tumor volume specifically in castrated Ptenpc-/- mice 
(Figure 3a; Extended Data 8c), with normalization of glands impacted by prostate cancer 
and a major reduction in Ki-67 positive cells (Figure 3b-d; Extended Data 8d). Critically, 
AR target genes were robustly down-regulated in Ptenpc-/-;IL23ko when compared to 
Ptenpc-/-;IL23wt prostate tumors (Figure 3e). These data were then also validated in 
TRAMP-C1 allograft mice reconstituted with IL23wt and IL23ko BM precursors (yielding 
TRAMP-C1 IL23wt and TRAMP-C1 IL23ko mice) (Extended Data 9a). In TRAMP-C1 
IL23ko mice, the absence of IL23 in the myeloid compartment significantly delayed the 
emergence of CRPC as demonstrated by decreased tumor size and tumor cell proliferation as 
well as reduced AR driven target gene expression with a significant survival advantage 
demonstrated for the TRAMP-C1 IL23ko mice (Figure 3f-h; Extended Data 9b-c). Critically, 
the IL23ko BM reconstitution did not alter the recruitment of MDSCs into the tumors and 
spleens of reconstituted mice (Extended Data 9 d-e). Of note, treatment with αIL23 
antibodies or genetic inactivation of IL23R in NSG™ TRAMP-C1 allografts confirmed 
these results (Figure 3i-j), demonstrating that IL23 directly promotes castration resistance by 
binding the IL23R present on tumor cells.
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IL-23 has been reported to regulate the activation of STAT3/RORγ expression in naive CD4 
T cells26–28; both STAT3 and RORγ can impact AR signaling in prostate cancer29,30. We 
therefore evaluated whether IL23 secreted by MDSCs impacted the STAT3/RORγ axis in 
prostate cancer in a non-cell autonomous manner. Inactivation of IL23 in the myeloid 
compartment of castrated Ptenpc-/- mice significantly decreased overall tumor levels of 
pSTAT3 and RORγ in vivo (Figure 3k-m; Extended Data 8d); this was also the case in the 
TRAMP-C1 model (Extended Data 9f-h). RORγ inhibition in vitro also abrogated the 
proliferative advantage conferred by MDSC C.M. or IL23 treatment in TRAMP-C1 cells 
kept in F.A.D., and inhibited the transcription of the full-length form of the AR and its 
constitutive active splice variant (ARv4) as well as downstream AR target genes (Figure 3n-
o). Altogether, these data demonstrate that IL23 released by MDSCs into the tumor 
microenvironment acts directly on the pSTAT3/RORγ axis to drive the transcription of AR 
and its splice variant and downstream target genes, thus favoring the proliferation and 
survival of the prostate cancer cells in androgen ablation conditions.
IL23 targeting improves the efficacy of ADT
To evaluate the therapeutic relevance of our findings, we next assessed whether IL23 
inhibition by antibody blockade could reverse castration resistance in Ptenpc-/- mice. Since 
anti-IL23 antibodies are currently being evaluated in clinical trials for the treatment of 
autoimmune diseases31 including psoriasis and are clinically well tolerated32, we treated 
mice carrying Ptenpc-/- tumors that had become resistant to surgical castration with an anti-
IL23 antibody (αIL23) in combination with the AR antagonist enzalutamide (ENZA; Figure 
4a). ENZA is a standard of care for the treatment of patients with CRPC after first line 
ADT2,33. Our preclinical study showed that αIL23 increased the efficacy of ENZA (Figure 
4b-c); in mice treated with αIL23 and ENZA we observed a normalization of prostate 
glands impacted by cancer (Figure 4b; Extended Data 10a), with decreased tumor volume 
(Figure 4c) and proliferation (Extended Data 10a-b), whereas in mice treated with ENZA 
alone the treatment was ineffective. Combined αIL23 and ENZA were associated with a 
robust inhibition of the AR activity and induction of tumor apoptosis (Figure 4e-g). Taken 
together, these data demonstrate that anti-IL23 treatment can reverse castration resistance in 
prostate cancer and enhance the efficacy of ENZA.
Discussion
Our study has identified IL23 production by MDSCs as a driver of CRPC and adds novel 
mechanistic insights on how prostate cancers can become insensitive to androgen 
deprivation and AR blockade. We also report on a novel role for MDSCs in cancer, 
describing an unexpected function for this immune subset. Previous data demonstrated that 
MDSCs can support tumorigenesis in many cancers through different mechanisms15,17,18 
with preclinical studies indicating that the inactivation of MDSCs increased immune-
checkpoint blockade efficacy in CRPC models16. IL23 has also been previously implicated 
in cancer progression in a different tumor-context as a regulator of the pro-tumor immune 
response34–36. However, the discovery described herein that IL23 produced by MDSCs 
regulates castration resistance in prostate cancer by sustaining AR signaling was previously 
unknown, and adds novel mechanistic insights on how these immune cells support 
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tumorigenesis. This work also proves that inhibition of IL23 can reverse ADT resistance in 
men suffering from advanced prostate cancer (Extended Data 10c).
In conclusion, we have described a novel immunotherapeutic strategy for treating advanced 
prostate cancer that unlike most others is not focused on re-activating the function of 
cytotoxic T lymphocytes against tumor cells. Immunotherapeutic strategies reactivating 
cytotoxic T-cells by immune checkpoint blockade have been, to date, only active against a 
small subset of prostate cancers characterized by DNA repair defects and higher neo-antigen 
loads with increased T lymphocyte infiltration37,38. Our results demonstrate, however, that 
MDSCs are a major player in prostate cancer endocrine resistance and that immunotherapies 
targeting the blockade of either MDSC recruitment into tumor, or the direct inhibition of 
IL23 can be effective therapeutic strategies for patients suffering from these lethal and 
common diseases. Since anti-IL23 antibodies have been well-tolerated in clinical trials 
involving patients with autoimmune diseases31, these deserve to be clinically evaluated in 
men suffering from lethal prostate cancer. We envision that this novel immunotherapeutic 
strategy targeting paracrine IL23 in combination with established endocrine anticancer 
treatments is highly likely to improve treatment outcome for this commonest of male 
cancers.
Methods
Animals
All mice were maintained under specific pathogen-free conditions in the IRB facility and 
experiments were performed according to national guidelines and regulations. All the animal 
experiments were approved by the local ethics committee (TI13/2015 and TI04/2017). Male 
C57BL/6, FVB, NSG™, NOD SCID mice 6–8 weeks of age were purchased from Jackson 
Laboratories (Envigo) and acclimated for at least a week before use. Male C57BL/6 
IL-23p19KO (IL23ko) mice28 were kindly provided by Prof. Federica Sallusto (IRB, 
Bellinzona) and used 8 weeks old. Male Ptenpc-/- mice were generated and genotyped as 
previously described17. Female PtenloxP/loxP mice were crossed with male PB-Cre4 
transgenic mice and genotyped for Cre using following primers: primer 1 (5'-
AAAAGTTCCCCTGCTGATGATTTGT-3') and primer 2 (5'-
TGTTTTTGACCAATTAAAGTAGGCTGTG-3') for PTENloxP/loxP; primer1 (5’ 
TGATGGACATGTTCAGGGATC 3’) and primer2 (5’CAGCCACCAGCTTGCATGA 3’) 
for Probasin-CRE. Surgical castration was performed under anesthesia with isoflurane. Male 
Ptenpc-/- mice were 9/10 weeks old at the time of castration. Mice were monitored 
postoperatively for recovery from anesthesia and checked daily for 4 days postoperatively. 
Surgical skin clips were removed on postoperative day 5. Mice undergoing treatment were 
administered control vehicle or therapeutic doses of the appropriate agents. Any mouse 
suffering distress or greater than 15% weight loss during treatment was euthanized by CO2 
asphyxiation. At the completion of study, mice were euthanized by CO2 asphyxiation and 
tissue was collected for histology, mRNA analysis, protein analysis and single cell 
suspensions for flow cytometry. For allograft experiments 2,5x106 TRAMP-C1 cells, 
2,5x106 TRAMP-C1 IL23RKO or 2x106 MyC-CaP cells were injected subcutaneously into 
the flank of male C57BL/6 or FVB mice respectively. For xenograft experiments 3x106 
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LNCaP cells were suspended with or without 3x106 human BM-MDSCs in total of 100 μl 
PBS and Matrigel (1:1) and implanted subcutaneously into the flank of NOD SCID mice. 
When tumors were approximately 100 mm3 mice were randomized to the treatment groups. 
Tumor growth was monitored daily by measuring the tumor size with caliper. The tumor 
volume was estimated by calculating R1*R2*R3*4/3π, where R1 and R2 are the 
longitudinal and lateral radii and R3 is the thickness of tumor protruding from the surface of 
normal skin. Animals were sacrificed when the tumor reached approximately 600 mm3. The 
local ethic committee approved the conduct of the in vivo experiments with maximal tumor 
sizes of 1000 mm3.
Treatments
αCXCR2 (AZD5069; Astrazeneca) was administered with daily intraperitoneal injections at 
a final concentration of 100mg/kg on a Monday through Friday schedule. Control animals 
received vehicle. Enzalutamide (APExBio) was administered daily by oral gavage with a 
dose of 30mg/kg/day on a Monday through Friday schedule. Rat anti-IL23 antibody (100 ng 
per mouse; G23-8; IgG1, kappa; eBioscience) or rat IgG1 isotype control (eBioscience) was 
administered weekly via intraperitoneal injection. For in vivo macrophages depletion, mice 
were treated 400μg anti-CSF1R (clone BE0213, BioXCell; on Mondays, Wednesdays and 
Fridays).
Cell lines
TRAMP-C1 cells line, MYC-CaP cell line, and LNCaP cell line, VCaP cell line, 22Rv1 cell 
line, PC3 cell line were received by ATCC and no other authentication method was 
performed. TRAMP-C1 IL23Rko cell line was generated in the lab with CRISPR-Cas9 
methodology and authenticated by WB and FACS for the deletion of IL23R. All the cell 
lines were regularly tested for mycoplasma (MycoAlert Mycoplasma Detection kit).
Bone marrow reconstitution
Bone marrow was flushed from the femurs of male C57BL/6 or IL23p19ko mice under 
sterile conditions with RPMI 1640 using a 21-gauge needle. Mononuclear cells were 
filtered, collected and checked for viability using trypan blue. Before transplantation, bone 
marrow derived cells were depleted of CD3+ T cells, NK1.1+ NK cells and CD19+ B cells 
by magnetic bead separation (STEMCELL Technologies). Recipient C57BL/6 or Ptenpc-/- 
mice were lethally irradiated (900 rad) and transplanted i.v. two hours after with 107 viable 
bone marrow cells from either C57/BL6 or IL23p19ko mice. For TRAMP-C1 allografts, the 
animals were challenged s.c. with TRAMP-C1 cells upon BM engraftment. When tumors 
reached ≈ 100 mm3, mice were surgically castrated and monitored for tumor progression.
Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) was performed on castrated-Ptenpc-/- mice 0, 4, 8, 12 
and 16 weeks after surgical castration or on CTX IL23wt and CTX IL23ko Ptenpc-/- mice 4, 
8, 12 and 16 weeks after surgical castration using a 7T preclinical magnetic resonance 
scanner (Bruker, BioSpec 70/30 USR, Paravision 5.1) equipped with 450/675 mT/m 
gradients (slew-rate: 3400–4500T/m/s; rise-time 140 µs) and a mouse body volume coil. 
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Mice were under general anesthesia by 1.5–2% isoflurane vaporized in 100% oxygen (flow: 
1 L/min). Breathing and body temperature were monitored (SA Instruments, Inc., Stony 
Brook, NY, USA) and maintained around 30 breaths-per-minute and 37°C, respectively. 
MRI studies included a Rapid Acquisition with Relaxation Enhancement (RARE) High-
Resolution T2-weighted (T2w) sequence with fat suppression acquired in the axial plane 
(TR =3800ms, TE =45ms, FOV = 27mm x 18mm, spatial resolution = 0,094 x 0,087 mm/
pixel, scan time = 8 min, thickness 0.70 mm, 26 slices) and in the coronal plane (TR =3500 
ms, TE =38 ms, FOV = 33mm x 33mm, spatial resolution = 0,129 x 0,129 mm/pixel, scan 
time = 5 min, thickness 0.60 mm, 20 slices). Images were analyzed using NIH software 
MIPAV (version 7.4.0). Circumference of the whole prostate was outlined on each RARE 
T2w axial slice containing identifiable prostate and the number of bounded pixels in each 
slice was computed and added to yield the prostate volume. Coronal T2w images were used 
for an accurate identification of the basal and apical limits of the prostate.
Differentiation of BM-MDSCs in vitro
Murine BM-MDSCs were differentiated in vitro as previously described39. Briefly, bone 
marrow precursors were flushed from the femurs of C57/BL6 or IL23p19ko mice with 
RPMI 1640 medium. The cell pellet was resuspended (one femur in 10 ml) in RPMI 1640 
containing 10% heat-inactivated FBS and the cells were cultured in vitro in the presence of 
40 ng/ml GM-CSF and 40 ng/ml IL-6. On day 4, the cells were washed and resuspended 
with RPMI 1640 containing 10% heat-inactivated Charcoal Stripped-FBS. The day after the 
cells were stimulated with PMA/ionomycin and after 4 hours the supernatant was collected 
and stored at −80°C. Analysis of soluble molecules was conducted with Mouse 
CytokineMAP B version 1.0 by Rules Based Medicine (Austin, TX).
Human BM-MDSCs were differentiated in vitro seeding 106/ml bone marrow precursors in 
T25 flasks with RPMI 1640 containing 10% heat-inactivated FBS in the presence of 10 
ng/ml GM-CSF and 10 ng/ml IL-6 for 7 days40. Complete medium was changed when 
required. After 7 days, the cells were analyzed by flow cytometry for CD11b, CD33, CD15, 
HLA-DR expression and when the population CD11b+, CD33+, CD15+, HLA-DRneg was 
higher than 80% the cells were re-suspended in RPMI 1640 containing 10% heat-inactivated 
Charcoal Stripped-FBS and after one day stimulated with PMA/ionomycin for 5 hours. The 
supernatant was then collected and stored at −80°C.
In vitro culture experiments
Prostate cancer cell lines were starved in Charcoal Stripped FBS (CS-FBS) medium for 72h 
and then cultured with RPMI 1640 containing 10% heat-inactivated FBS (normal medium) 
or kept in full androgen deprivation medium (F.A.D.; RPMI 1640 containing 10% heat-
inactivated Charcoal Stripped-FBS plus Enzalutamide 10μM; F. A. D.). Then, the cells were 
stimulated with or without condition media obtained from activated BM-derived MDSCs, or 
recombinant IL23 (100ng/ml; R&D System), with or without αRORγ (5 μM; SR2211; 
Calbiochem®). Then the cells were analyzed for Crystal Violet assay (after 72h of colture, 
fold change compared with F. A. D. condition), stained with Annexin V/7AAD (after 72h of 
colture) or collected for RNA extraction (after 24h of culture; fold change compared with F. 
A. D. condition).
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Analyses of IL23 and IL23R mRNA expression in clinical tumors
HSPC RNA-Seq data for 550 patients was downloaded from the UCSC Cancer Browser 
(https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/). mCRPC RNA-Seq data for 122 
mCRPC patients was generated as part of SU2C effort41. The paired-end transcriptome 
sequencing reads were aligned to the human reference genome (GRCh37/hg19) using 
Tophat242 (Tophat 2.1.0). Gene expression, as fragments per kilobase of exon per million 
fragments mapped (FPKM; normalized measure of gene expression), was calculated using 
Cufflinks43. MDSC marker (CD11b, CD33, CD14 and CD15) positive and negative was 
defined by the high quantiles and low quantiles RNA expression of each transcript and IL23/
IL23R expression level in each biomarker groups were compared by student t test. In order 
to compare gene expression level between TCGA and SU2C with minimum experimental 
bias, we only included genes expressed in both TCGA and SU2C with median expression 
level (FPKM) > 0. The gene expression levels in each sample were quantile normalized, and 
IL23 expression levels in HSPC and CRPC were compared using t test.
Human organoids
Organoids were grown in 3D Matrigel® (cat.356231, Corning) under prostate epithelial 
conditions44. Cell viability was measured using 3D CellTiter-Glo® 3D reagent (cat.G9681, 
Promega) by quantifying metabolically active cells releasing ATP. Cell line-derived 
organoids were plated at a density of 2000 cells per well in 96-well optical plates (cat.3610, 
Corning) embedded in Matrigel® as hanging drops (5μl per well). Cells were treated with 
recombinant IL23 (cat 300-01A, PeproTech) at 100ng/ml or culture with Enzalutamide 
(10uM) with or without recombinant IL23. The luminescence measurement was performed 
after 7 days in culture. Each IL23 condition was normalized for its experimental control.
Immune tumor microenvironment characterization
Tumors were disaggregated and digested in collagenase D and DNAse for 30 minutes at 
37°C to obtain single-cell suspension. For intracellular cytokine detection cells where 
stimulated for 5 hours with PMA/ionomycin plus Golgi Plug. After neutralization of 
unspecific binding with αCD16/CD32 (clone 93), single-cell suspensions were stained with 
specific mAb (primary antibodies directly conjugated) to assess the phenotype and diluted 
1:200. The antibodies used were: αCD45 (clone 30-F11, Lot. B235438); αLy-6G (clone 
1A8, Lot B194432); αLy6C (clone HK1.4, Lot. B243043), αCD11b (clone M1/70, Lot. 
B233927); αF4/80 (clone BM8, Lot. 4305911), αCD206 (clone C068C2, Lot. B230155), 
αCD11c (clone N418, Lot. B226270), αB220 (clone RA3-6B2, Lot. B210434), αCD3 
(clone 145-2C11, Lot. B241616), αCD8 (clone 53-6.7, Lot. B193838), αCD4 (clone GK1.5, 
Lot. B240053), αNK1.1 (clone PK136, Lot. 4291566), αCD90.2 (clone 30-H12, Lot. 
B190542), αPDL1 (clone 10F.9G2, Lot. B191993), αEpCAM (clone G8.8, Lot. B230070), 
αPan-Cytokeratin (clone C11, Lot. 4528S), αIL17 (clone TC11-18H10.1, Lot. B201753), 
αIL23p19 (clone FC23CPG, Lot. 4321359), Isotype (Rat/IgG1,kappa, eBRG1) αIL23R 
(clone 12B2B64, Lot. 4321359), For flow gating we used isotype controls of florescence 
minus one controls. All the antibodies were purchased from eBioscience or Biolegend. 
Samples were acquired on a BD Fortessa flow cytometer (BD Biosciences). Data were 
analyzed using FlowJo software (TreeStar, Ashland, OR).
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Murine Immunohistochemistry and Immunofluorescence
For immunohistochemistry (IHC), tissues were fixed in 10% formalin (ThermoScientific, 
5701) and embedded in paraffin in accordance with standard procedures. Preceding 
immunohistochemical staining, tumor sections (4µm) were exposed to two washes with 
OTTIX plus solution (Diapath, X0076) and subsequent hydration with OTTIX shaper 
solution (Diapath, X0096) followed by deionized water. Antigen unmasking was performed 
by heating sections in the respective pH solutions based on the antibodies used at 98°C for 
20 minutes. Subsequently the sections were blocked for peroxidases and nonspecific binding 
of antibodies using 3% H2O2 (VWR chemicals, 23615.248) and Protein- Block solution 
(DAKO Agilent technologies, X0909) respectively for 10 minutes each split by 0.5% PBST 
washing. H&E staining was performed according to standard procedures. Sections were 
stained for anti-Ki67 (Clone SP6; Lab Vision Corporation), anti-pSTAT3 (TYR705; clone 
D3A7; Cell Signaling). Images were obtained using objectives of 5x, 10x, 40x magnification 
and Pixel image of 1.12µm and 0.28µm respectively. All the quantifications have been done 
using the public online software ImmunoRatio (153.1.200.58:8080/iimunoratio/). For the 
immunofluorescence (IF) staining, tissue paraffin embedded sections were stained for 4′,6-
Diamidine-2′-phenylindole dihydrochloride(DAPI) (#70238421, Roche), anti-IL23 
(ab45420; Abcam), anti-Ly6G (RB6-8C5; GeneTex). Confocal images were obtained with 
the Leica TCS SP5 confocal microscope using × 10/1.25 oil.
In vitro T cell suppression assay
In vitro suppression assays were carried out in RPMI/10% FCS in 96-well U-bottom plates 
(Corning, NY). Naive splenocytes were labeled with 5μM CFSE (Molecular Probes) and 
activated in vitro with anti-CD3 and anti-CD28 beads (Invitrogen) according to the 
manufacturer's instructions. Conditioned media of BM-MDSCs was added to the culture. 
After 3 days, the proliferation of CFSE-labelled CD8+ T cells was analyzed by BD Fortessa.
CRISPR-Cas9 transfection
TRAMP-C1 cells were grown in 75cm2 flask to a 50-60% confluence in DMEM medium 
supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin 
and 2 mM L-glutamine. The transfection of the IL23R CRISPR/Cas9 KO plasmid (Santa 
Cruz Biotechnology) was performed using jetPRIME® transfection reagent according to the 
manufacturer protocol at the 1:2 DNA/jetPRIME® ratio. 24h after transfection, GFP 
transduced cells were sorted to 99% purity and single-cell plated in 96-well plates. At day 7 
after sorting the grown cell clones were moved into 24well plates for further expansion. The 
knock-down of IL23R gene in each cell colony was confirmed by Western blot.
NanoString
The nCounter analysis system (NanoString Technologies, Seattle, WA) was used to screen 
for the expression of signature genes associated with cancer-inflammation pathway. Two 
specific probes (capture and reporter) for each gene of interest were employed. Briefly, 5ul 
of RNA (the concentration is higher than 25 ng/ul) was hybridized with customized Reporter 
CodeSet and Capture ProbeSet as Mouse PanCancer Immune Profiling Panel including 700 
selected genes (NanoString Technologies) according to the manufacturer’s instructions for 
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direct labeling of mRNAs of interest with molecular barcodes without the use of reverse 
transcription or amplification. Total RNA was quantified by NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies, Wilming-ton, DE) and RNA quality was assessed 
using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). The hybridized 
samples were then recovered in the NanoString Prep Station and the mRNA molecules were 
counted with the NanoString nCounter. For expression analysis, each sample profile was 
normalized to geometric mean of 20 housekeeping genes included in the panel.
Immune tumor microenvironment characterization in prostate cancer patients
Tumors were disaggregated and digested in collagenase I and DNAse for 20 minutes at 37°C 
to obtain single-cell suspension. For intracellular cytokine detection cells where stimulated 
for 5 hours with PMA/ionomycin plus Golgi Plug. Single-cell suspensions were stained with 
specific mAb diluted 1:200 (primary antibodies directly conjugated) to assess the phenotype. 
The antibodies used were: αCD45RA (clone MEM-56, 1:50); αCD33 (clone WM53); 
αCD11b (clone ICRF44); αCD15 (clone W6D3), αHLA-DR (clone L243), αIL23p19 
(clone 23DCDP). For flow gating we used isotype controls of florescence minus one 
controls. All the antibodies were purchased from eBioscience or Biolegend. Samples were 
acquired on a BD Fortessa flow cytometer (BD Biosciences). Data were analyzed using 
FlowJo software (TreeStar, Ashland, OR).
Protein profile
Plasma pools of CSPCs or CRPCs patients were processed as indicated in Human XL 
Cytokine Array Kit (R&D Systems). Pools of tissue lysates of sham and castrated Ptenpc-/- 
tumors were processed as indicated in Mouse XL Cytokine Array Kit (R&D Systems). 
Developed films were scanned, obtained images were analyzed using ImageJ 1.43u and 
background signals were subtracted from the experimental values.
Multiplex IF in formalin fixed paraffin embedded tissue section
PMN-MDSC panel (CD15, CD11b, CD33 and EpCAM)—Multiplex 
immunofluorescence for CD15 (#M3631, Dako, clone Carb-3), CD33 (#ab11032, Abcam, 
clone 6C5/2), CD11b (#ab52477, Abcam, clone EP1345Y) and EpCAM Alexa Fluor® 647 
conjugate (#5447S, CellSignaling, clone VU1D9) was performed using 4µm sections of 
FFPE prostate tumor samples by sequential staining after antigen retrieval in CC1 (pH 8.5) 
(#950-224, Ventana) in water bath at 98°C for 36 minutes. First, mouse monoclonal (IgG1) 
antibody anti-CD33 (1:100 dilution), mouse monoclonal (IgM) anti-CD15 (1:200 dilution) 
and rabbit monoclonal (IgG) antibody anti-CD11b (1:100 dilution) were incubated for one 
hour after blocking with 10% goat serum for 30 minutes. Primary antibodies were detected 
with goat anti-mouse IgG1 Alexa Fluor® 555-conjugated (#A21127, Life Technologies), 
goat anti-mouse IgM Alexa Fluor® 488-conjugated (#A21042, Life Technologies) and goat 
anti-rabbit IgG (H+L) Alexa Fluor® 700-conjugated (#A21038, Life Technologies) 
antibodies for 30 minutes. Next, tissue sections were treated with 5% mouse/rabbit normal 
serum for 30 minutes, followed by incubation with mouse monoclonal (IgG1) anti EpCAM 
antibody conjugated to Alexa Fluor® 647 (dilution, 1:200) for one hour. The samples were 
washed three times for 5 minutes with TBS-Tween 0.05% between incubations. Nuclei were 
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counterstained with 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI) (#70238421, 
Roche) and tissue sections were mounted with ProLong Gold antifade reagent (#P36930, 
Molecular Probes).
CD15, IL-23 and EpCAM—IF was performed on 4µm FFPE tissue sections using an 
automated staining platform (Bond-RX, Leica Microsystems). Briefly, antigen retrieval was 
achieved using ER1 (pH 6.0) (#AR9961, Leica Biosystems) for 30 minutes. Sections were 
blocked in 10% normal goat serum for 30 min at room temperature. Primary antibodies 
mouse monoclonal (IgM) anti-CD15 (#M3631, Dako, clone Carb-3, dilution 1:200), rabbit 
monoclonal (IgG) antibody anti-IL23 (#ab190356, Abcam, clone EPR5585(N), dilution 
1:100) and mouse monoclonal (IgG1) anti EpCAM antibody (#2929S, CellSignaling, clone 
VU1D9, dilution 1:500) were incubated for one hour. Primary antibodies were detected with 
goat anti-rabbit (H+L) Alexa Fluor® 555-conjugated (#A21429, Life Technologies), goat 
anti-mouse IgM Alexa Fluor® 488-conjugated (#A21042, Life Technologies) and goat anti-
mouse IgG1 Alexa Fluor® 647-conjugated (#A21240, Life Technologies) for 30 minutes. 
Nuclei were counterstained with 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI) 
(#70238421, Roche) and tissue sections were mounted with ProLong Gold antifade reagent 
(#P36930, Molecular Probes).
Microscopy and image acquisition—After staining, slides were scanned using the 
multi-spectral camera provided by Vectra® (Perkin Elmer) system. The number of images 
collected per case was dependent on tumor size (Min.=1, Max.=18, Average=12). 
Quantification of PMN-MDSC like cells (CD15+CD33+CD11b+) was performed using 
inForm v2.1.1 software (PerkinElmer) and the density of cells of interest are presented as 
number of cells per mm2. Tissue segmentation algorithm based on EpCAM positivity was 
used to separate tumor from adjacent stroma. The algorithm was trained to perform cell 
segmentation using counterstain based segmentation achieved with nuclear DAPI staining. 
Phenotype determination was based on positivity for CD15, CD33 and CD11b. Cells in 
tumor areas selected by the algorithm were then separated into bins as follows: 
CD15+CD33+CD11b+ were called PMN-MDSC like cells and CD15- CD11b+ cells were 
called CD15- CD11b+ cells. All tissue segmentation, cell segmentation and phenotype 
determination maps were reviewed by a pathologist.
Antibody specificity validation for Multiplex IF
IHC was performed on 4µm formalin-fixed paraffin embedded (FFPE) tissue sections using 
an automated staining platform (Bond-RX, Leica Microsystems). Optimal antibody 
concentrations were determined with primary antibodies against CD15 (#M3631, Dako, 
clone Carb-3, dilution 1:200), CD33 (#ab11032, Abcam, clone 6C5/2, dilution 1:100), 
CD11b (#ab52477, Abcam, clone EP1345Y, dilution 1:100) IL23 (#ab190356, Abcam, 
clone EPR5585 (N), dilution 1:100) and EpCAM (#2929S, CellSignaling, clone VU1D9, 
dilution 1:500). Antibody labelling was detected with the Bond Polymer Refine Detection 
Kit (#DS9800, Leica Microsystems). 3,3-diaminobenzidine tetrahydroxychloride (DAB) 
was used as chromogen and the slides were counterstained with hematoxylin. Human 
control included colorectal specimens. In each staining batch, positive and negative controls 
were incubated with and without primary antibody.
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RNA expression/quantitative real-time PCR
RNA isolation (TRIzol, Qiagen) and retro-transcription with SuperScriptIII (Invitrogen, 
11752-250) were performed according to the manufacturer’s instructions. Quantitative PCR 
(qPCR) reactions (Bio-Rad) were performed using KAPA SYBR FAST qPCR green 
(KK4605; Applied Biosystems) and the specific primers reported below. Primer sequences 
were obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/index.html) or 
BIORAD. Each expression value was normalized by HPRT or GADPH level as reference.
The primer sequences used were as follows:
CXCL1 forward, 5'-CTGGGATTCACCTCAAGAACATC-3; reverse, 5' – 
CAGGGTCAAGGCAAGCCTC-3’. CXCL2 forward, 5'-GCGTCACACTCAAGCTCTG-3’; 
reverse, 5'-CCAACCACCAGGCTACAGG-3’; CXCL3 forward, 5'-
ATCCCCCATGGTTCAGAAA-3’; reversal, 5’-ACCCTGCAGGAAGTGTCAAT-3’; 
CXCL5 reversal, 5’-GCGGCTATGACTGAGGAAGG-3’; forward, 5'-
GTTCCATCTCGCCATTCATGC-3’; GAPDH reversal, 5'-
TGTAGACCATGTAGTTGAG-3’; forward, 5'-AGGTCGGTGTGAACGGATT-3’. IL23p19 
forward, 5’-CCAGCAGCTCTCTCGGAATC-3’; reverse, 5’-
TCATATGTCCCGCTGGTGC-3’. BIORAD primers used were: HPRTPrimePCR™ 
PreAmp for SYBR® Green Assay: Hprt, Mouse qMmuCID0005679; AR PrimePCR™ 
PreAmp for SYBR® Green Assay: Ar, Mouse BIORAD qMmuCID0005164; 
NKX3.1PrimePCR™ PreAmp for SYBR® Green Assay: Nkx3-1, Mouse 
qMmuCED0046482; PBSNPrimePCR™ PreAmp for SYBR® Green Assay: Pbsn, Mouse 
qMmuCID0017831; FKBP5PrimePCR™ PreAmp for SYBR® Green Assay: Fkbp5, Mouse 
qMmuCID0023283.
Western blot analyses and protein detection
Tissue and cell lysates were prepared with RIPA buffer (1x PBS, 1% Nonidet P40, 0.5% 
sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail; Roche). Total protein 
concentration was measured using BCA Protein Assay Kit (Cat: 23225; Pierce, Rockford). 
Equal amounts of proteins were separated by SDS-PAGE and western blotted onto a 0.45 
μm-nitrocellulose membrane. Membranes were blocked in 5% defatted milk or 5% BSA in 
Tris-buffered saline containing 0.1% Tween-20 (TBST), probed with diluted antibodies and 
incubated at 4°C overnight. The following primary antibodies were utilized: rabbit 
polyclonal anti-HSP90 (1:1000 dilution, Cell Signaling), rabbit polyclonal anti-phospho-
Stat3 (Tyr705) (1:1000 dilution, Cell Signaling), rat monoclonal anti-RORγt (5:1000 
dilution, clone AFKJS-9, eBioscence), rabbit polyclonal anti-IL23R (H-300) (1:1000 
dilution, Santa Cruz). After washing in TBST, the membrane was incubated with secondary 
antibody conjugated with horseradish peroxidase (HRP) (dilution 1:5000, Cell Signaling). 
The protein bands were visualized using the ECL Western Blotting Substrate (Pierce).
Human prostate samples
These were acquired from mCRPC patients who had given their written informed consent to 
institutional protocols approved either by the Royal Marsden NHS Foundation Trust 
Hospital (London, UK) Ethics Committee (reference no. 04/Q0801/60), the IRCCS 
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Ospedale San Raffaele (Milan, Italy) Ethics Committee (reference no. 99/INT/2004; 58/INT/
2010), or the Azienda Ospedaliera di Padova (Padova, Italy) Ethics Committee (reference 
no.CESC/958P/2005). Human biological samples were sourced ethically and their research 
use was in accord with the terms of the informed consent provided. Fifty-one patients with 
CRPC treated at The Royal Marsden NHS Foundation Trust Hospital with sufficient 
formalin-fixed, paraffin-embedded, had matching CSPC and CRPC biopsies identified for 
multiplex IF (see Table 1). Four patients with CRPC, enrolled at Azienda Ospedaliera di 
Padova, and four patients with CSPC, enrolled at IRCCS Ospedale San Raffaele, were 
selected to perform the immune tumor microenvironment characterization by flow cytometry 
analyses. Case selection was blinded to baseline characteristics, treatments received, clinical 
outcome and molecular characterization to reduce any potential selection bias. Finally, 
plasma from 120 CRPC patients with sufficient samples stored (including 28 plasma 
samples within 40 days of CRPC biopsy) and 20 CSPC patients were analyzed for IL23 
levels.
Statistical analysis and reproducibility—Data analyses used GraphPad Prism version 
7. The data are presented as mean ± standard error of the mean, individual values as scatter 
plot with column bar graphs and were analyzed using Student’s t-tests (paired or unpaired 
according to the experimental setting) by a two-sided and, when indicated, followed by 
Wilcoxon post-test. One-way ANOVA was used to compare three or more groups in time 
point analyses. Differences were considered significant when P < 0.05 and are indicated as 
NS, not significant, *P < 0.05, **P < 0.01, ***P < 0.001. Non-parametric tests were applied 
when variables were not normally distributed using the SPSS statistical software. N values 
represent biological replicates. Survival curves were compared using the Log-rank test 
(Mantel-Cox). Due to evidence of overdispersion, tumor-infiltrating PMN-MDSC 
(CD15+CD11b+CD33+ EpCAM-) and CD15-CD11b+ cells were analyzed using mixed 
effect negative binomial regression model (with per patient random intercept) when 
comparing paired biopsies, and a negative binomial regression model was used when 
analyzing the association at CRPC biopsies with IL23. PMN-MDSC (Coefficient: 1.49; 95% 
CI: 0.83 to 2.15; P<0.001); CD15-CD11b+ cells (Coefficient: 0.43; 95% CI: 0.04 to 0.83; 
P=ns). All the statistics and reproducibility are reported in the figure legend. For animal 
studies, sample size was defined on the basis of past experience with the models15, to detect 
differences of 20% or greater between the groups (10% significance level and 80% power). 
For ethical reasons the minimum number of animals necessary to achieve the scientific 
objectives was used. Animals were allocated randomly to each treatment group. Different 
treatment groups were processed identically and animals in different treatment groups were 
exposed to the same environment.
Data availability statement—Source Data for the main and Extended Data Figures are 
provided in the manuscript. CSPC and mCRPC tumour biopsy mRNA seq data that support 
the findings of this study are available in the SU2C-PCF IDT cBioportal and through 
dbGAP with the identifier phs000915.v1.p141.
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Extended Data
Extended Data 1. Multispectral images of PMN-MDSCs in human biopsies and set up of the 
different CRPC mouse models.
a, Multispectral microscopy images (EpCAM yellow, CD15 green, CD33 red; CD11b pink) 
of castration sensitive vs castration resistant prostate cancers. n=3 biological independent 
patients. Scale Bar 20μM. b, Quantification of the number of CD11b+ CD15- cells within 
the tumor of castration sensitive vs castration resistant prostate cancers (CSPCs, n=51 vs 
CRPCs, n=51 biological independent patients). Cells were counterstained with the nuclear 
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marker DAPI (blue). Statistical analyses (negative binomial regression model): P=0.062. c, 
MRIs of one representative Sham-operated (Sham) or surgical castrated (CTX) Ptenpc-/- 
mouse of the three analyzed at different time points. d, Waterfall plot depicting proportional 
change in tumor response for Sham (n=3) and CTX (n=3) Ptenpc-/- mice. e, Prostate PMN-
MDSCs frequencies determined by flow cytometry in Sham (n=3) and CTX (n=3) Ptenpc+/+ 
mice (12 weeks after castration). Statistical analyses (two sided unpaired t test): P=0.85. f, 
Schematic representation of the experiment. Six-week-old C57BL/6 males were challenged 
s.c. with TRAMP-C1 cells. When tumors reached ≈ 100 mm3, mice were sham-operated 
(Sham, n=9) or surgically castrated (CTX, n=5). g, Tumor PMN-MDSCs frequencies 
determined by flow cytometry during CS and CR phase. Sham CS n=5, CTX CS n=4, Sham 
CR n=8, CTX CR n=6. h, Schematic representation of the experiment. Six-week-old FVB 
males were challenged s.c. with MyC-CaP cells. When tumors reached ≈ 100 mm3, mice 
were sham-operated (Sham, n=3) or surgically castrated (CTX, n=3). i, Tumor PMN-
MDSCs frequencies determined by flow cytometry during CS and CR phase. Sham CS n=3, 
CTX CS n=4, Sham CR n=4, CTX CR n=3. b,d,e,g,i, Data are reported as mean ± SEM. 
d,g,i, Statistical analyses (Unpaired two-sided t-test): ns, not significant; *P <0.05; **P 
<0.01; ***P <0.001. f,h, Statistical analyses (two sided unpaired t test followed by 
Wilcoxon post-test): *P <0.05.
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Extended Data 2. Multiparametric flow cytometry analysis of myeloid populations in the tumors 
of different CRPC mouse models.
a, Gating strategy relative to the quantification of PMN-MDSCs in the tumor of Sham and 
CTX-operated mice for Ptenpc-/-, TRAMP-C1 and MyC-CaP models. b, Representative dot 
plot reporting the Ly6G and Ly6C positive cells in the tumor of Sham and CTX-operated 
mice for Ptenpc-/-, TRAMP-C1 and MyC-CaP models. Data were validated in at least three 
biological independent animals. c, Representative dot plot and quantification of CD11b+ 
F4/80+ cells and CD11c+ CD206- (M1-like) or CD11c- CD206+ (M2-like) macrophages in 
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the tumor of Sham and CTX-operated mice for Ptenpc-/- (Sham n=5, CTX n=9), TRAMP-C1 
(Sham n=7, CTX n=6), and MyC-CaP (Sham n=4, CTX n=4), models. Data were reported 
as mean ± SEM. Statistical analyses (Unpaired two-sided t-test): **P <0.01.
Extended Data 3. Factors secreted by MDSCs promote insensitivity to androgen deprivation in 
androgen-dependent murine and human prostate cancer cell lines and CXCR2 antagonist 
impairs MDSCs tumor recruitment in Ptenpc-/- mice.
a, Representative dot plot reporting the BM-MDSCs upon in vitro differentiation. Data were 
validated in two biological independent experiments. b, Experimental scheme. c, Cell 
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proliferation of MyC-CaP cells (None n=5, C.M. BM-MDSCs n=3, F.A.D. n= 13, F.A.D. + 
BM-MDSCs n= 13 biological independent samples). d, Percentage of AnnexinV and 
7AAD-negative MyC-CaP cells. e, Percentage of AnnexinV and 7AAD-positive MyC-CaP 
cells. f, qRT-PCR analyses of the indicated genes in MyC-CaP cells. g, h, i, Cell 
proliferation of VCaP (None n=4, C.M. hBM-MDSCs n=4, F.A.D. n=7, F.A.D. + hBM-
MDSCs n=8 biological independent samples), 22Rv1 (None n=4, C.M. hBM-MDSCs n=8, 
F.A.D. n=8, F.A.D. + hBM-MDSCs n=4 biological independent samples), and PC3 (None 
n=4, C.M. hBM-MDSCs n=8, F.A.D. n=4, F.A.D. + hBM-MDSCs n=8 biological 
independent samples) prostate cancer cells. j, Tumor MDSCs frequencies determined by 
flow cytometry of prostate tumors of CTX Ptenpc-/- mice treated or not with CXCR2 
antagonist (αCXCR2) at completion of the study (12-weeks upon CTX). CTX CS n=3, CTX
+ αCXCR2 CS n=3, CTX CR n=4, CTX+ αCXCR2 CR n=7 biological independent 
animals. k, Cell proliferation of TRAMP-C1 cells after 72h of treatment with CXCR2 
antagonist (αCXCR2) l, qRT-PCR analyses of the indicated genes in TRAMP-C1 cells after 
24h of treatment (fold change compared with F. A. D. condition). k, l, Aggregated data from 
three independent experiments are reported, fold change compared with F. A. D. condition. 
c-l, Data were reported as mean ± SEM. c-f, n=3 biological independent samples d,e,g-j, 
Statistical analyses (Unpaired two-sided t-test): ns, not significant; *P <0.05; **P <0.01; 
***P <0.001. c,f, Statistical analyses (two sided unpaired t test followed by Wilcoxon post-
test): *P <0.05.
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Extended Data 4. Impaired tumor recruitment of MDSCs enhances response to surgical 
castration in different allograft models of prostate cancers.
a, Schematic representation of the experiment. Six-week-old C57BL/6 males were 
challenged s.c. with TRAMP-C1 cells. When tumors reached ≈ 100 mm3, mice were 
surgically castrated and left untreated (CTX, n=8) or treated with CXCR2 antagonist (CTX 
+ αCXCR2, n=9). Representative flow cytometry plots of PMN-MDSCs (CD11b+ Ly6G+ 
cells, gated on CD45+ cells) in tumors for each experimental condition. b, qRT-PCR 
analyses of the indicated genes in the prostate tumors of CTX and CTX + αCXCR2 (n=3 
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per group). Data were reported as mean ± SEM. Statistical analyses (Unpaired two-sided t-
test):*P <0.05; ***P <0.001. c, Average tumor volume (±SE) for each experimental group. 
Statistical analyses (Unpaired two sided t test followed by Wilcoxon post-test): ***P 
<0.001. d, Survival curves are reported in Kaplan-Meier plot. Statistical analyses (two sided 
Log rank test): ***P <0.001. e, Schematic representation of the experiment. Six-week-old 
FVB males were challenged s.c. with MyC-CaP cells. When tumors reached ≈ 100 mm3, 
mice were surgically castrated and left untreated (CTX, n=5) or treated with CXCR2 
antagonist (CTX + αCXCR2, n=5). Representative flow cytometry plots of PMN-MDSCs 
(CD11b+ Ly6G+ cells, gated on CD45+ cells) in tumors for each experimental condition. f, 
qRT-PCR analyses of the indicated genes in the prostate tumors of CTX and CTX + 
αCXCR2 (n=3 per group). Data were reported as mean ± SEM. Statistical analyses 
(Unpaired two-sided t-test):**P <0.01; ***P <0.001. g, Average tumor volume (±SEM) for 
each experimental group. Statistical analyses (two sided unpaired t test followed by 
Wilcoxon post-test): *P <0.05. h, Survival curves reported as Kaplan-Meier plot. Statistical 
analyses (two sided Log-rank test): **P <0.01. i, Schematic representation of the 
experiment. Six-week-old NOD SCID males were challenged s.c. with LNCaP cells or with 
LNCaP cells and hBM-MDSCs. When tumors reached ≈ 70 mm3, mice were sham-operated 
(Sham, n=5) or sham-operated and injected every three days i.p. with 3x106 hBM-MDSCs 
(Sham + hBM-MDSCs, n=5) or surgically castrated and left untreated (CTX, n=8) or treated 
with hBM-MDSCs (CTX + hBM-MDSCs, n=5). j, Average tumor volume (±SEM) for each 
experimental group. Statistical analyses (Unpaired two sided t test followed by Wilcoxon 
post-test): **P <0.01.
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Extended Data 5. IL23 pathway is the most up-regulated in the tumor upon castration.
a, Gene expression of selected genes determined by NanoString nCounter gene expression 
assay in Sham Ptenpc-/- and CTX Ptenpc-/- tumors. Data are shown as pool of n=5. b, 
Analyses of the conditioned media of BM-derived MDSCs tested for the indicated soluble 
molecules by Mouse CytokineMAP B version 1.0. The graph reports the concentration of 
the indicated soluble molecules as Log10 of the concentration found in the conditioned 
medium of BM-MDSCs, the values were subtracted of the background (culture medium). 
Data are shown as pool of n=10. c, qRT-PCR analyses of the indicated genes in Sham (n=6) 
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and CTX (n=6) Ptenpc-/- tumors. Data were reported as mean ± SEM of biological 
independent animals. Statistical analyses (Unpaired two sided t test): *P <0.05. d, Protein 
level of CXCL1, CXCL2 and CXCL5 in CTX Ptenpc-/- tumors. Data are analyzed as ratio 
between CTX (pool of 3 samples) and Sham (pool of 3 samples) Ptenpc-/- tumors and 
reported as fold increase in protein level. e-f, IL23R protein level analyzed by flow 
cytometry and western blot on TRAMP-C1 cells under normal culture condition (FBS) or 
androgen deprivation culture condition (CS-FBS). n=4 biological independent samples per 
group. f, Numbers indicate fold change in protein level. Loading control: anti–β–actin 
antibody. The WB was validated at twice. g, Protein profile of the plasma of CSPC and 
CRPC patients. Data are analyzed as ratio between CRPC (pool of 18 samples) and CSPC 
(pool of 17 samples) and reported as fold increase in protein level.
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Extended Data 6. Characterization of IL23+ cells in the tumor of CTX Ptenpc-/- mice and CRPC 
patients.
a, Multispectral microscopy images (EpCAM yellow, CD15 green, IL23 red) of three human 
castration resistant prostate cancers. b, Correlation analyses of the numbers of CD15- 
CD11b+ cells in the tumor and the IL23 levels in the plasma of CRPC patients (n=28). 
Statistical analyses (negative binomial regression model) p=0.63. c, d, IL23 and IL23R 
mRNA expression in the tumor of HSPCs (n=549) and mCRPCs (n=116). e, f, Expression of 
IL23 in PMN-MDSC marker (CD11b, CD33, CD15) positive HSPC or mCRPC patients. c-
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f, Statistical analyses (Unpaired two sided t test) are reported. g, Representative plots of 
IL23+, CD45+ and CD45-, Ly6Gbright CD11b+ and Ly6Gint CD11bint, CD11b+ F4/80+ cells 
pre-gated on the reported population in the tumor of CTX Ptenpc-/- mice. IL23 gate was 
decided based on Isotype control panel (insert). Pie reports the percentage of the different 
subsets gated on IL23+ cells in the tumor of Ptenpc-/- mice (Mean, n=9). h, qRT-PCR 
analyses of IL23 in the prostate tumors of castrated (CTX; n=6) or castrated and treated with 
CXCR2 antagonist (CTX + αCXCR2; n=7) Ptenpc-/- mice. Mean ± SEM. i, PMN-MDSCs 
and TAMs frequencies determined by flow cytometry in the tumor of castrated NSG™ 
TRAMP-C1 allografts upon treatment with Isotype, αCSF1R, αCXCR2. Data are reported 
as mean ± SE (n=3 per group). j, qRT-PCR analyses of IL23 in the tumor of castrated 
NSG™ TRAMP-C1 allografts upon treatment with Isotype (n=4), αCSF1R (n=5), αCXCR2 
(n=5). Data are reported as mean ± SEM. Each dot represents a biological independent 
animal. h, i, j, Statistical analyses (Unpaired two sided t test): *P <0.05; **P <0.01; ***P 
<0.01.
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Extended Data 7. BM-MDSCsIL23wt and BM-MDSCsIL23ko have equal secretome and equal 
immunosuppressive capability.
a, Correlation analyses of the gene expression of selected genes determined by NanoString 
nCounter gene expression assay in BM-MDSCsIL23wt and BM-MDSCsIL23ko reported by 
scatter plot analyses. Data are shown as pool of n=10. R2 values were determined using a 
linear regression analyses. b, Representative flow cytometry plots of CFSE dilution (gated 
on CD8+ cells) and quantification of proliferating CD8+ T cells exposed to C. M. from BM-
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MDSCsIL23wt or BM-MDSCsIL23ko. Mean ± SE of three independent biological samples. 
Statistical analyses (Unpaired two sided t test): **P <0.01; ***P <0.01.
Extended Data 8. Genetic inhibition of IL23 limits castration resistance in Ptenpc-/- mice.
a, Experimental set-up. Sham-operated (Sham) or Castrated (CTX) Ptenpc-/- mice were 
lethally irradiated and transplanted with BM precursors depleted by T, B, and NK cells from 
IL23wt and IL23ko mice. Then, monitored by MRI for tumor progression. b, Representative 
dot plot of BM precursors pre- and post-depletion of T, B, and NK cells. Data were validated 
in two biological independent experiments. c, Quantification of the tumor size of Sham-
operated Ptenpc-/-;IL23wt (n=4) and Ptenpc-/-;IL23ko (n=4), and castrated Ptenpc-/-;IL23wt 
(n=4) and Ptenpc-/-;IL23ko (n=7) mice at completion of the study is reported as fold increase 
of the prostate anterior lobe (AL) volume (fold change compared with CTX Ptenpc-/-;IL23wt 
group). Data are reported as mean ± SE. Statistical analyses (Unpaired two sided t test): **P 
<0.01, ***P <0.001. d, H&E, Ki-67, and pSTAT3Y705 immunohistochemical staining (Ki-67 
and pSTAT3Y705 brown; nuclei, blue) of one representative Ptenpc-/-;IL23wt and 
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Ptenpc-/-;IL23ko mouse of at least the three analyzed at completion of the study. Scale Bar 50 
or 25 μM.
Extended Data 9. Genetic inhibition of IL23 limits castration resistance in TRAMP-C1 allograft 
model in vivo.
a, Schematic representation of the experiment. Six-week-old C57BL/6 males were lethally 
irradiated and transplanted with BM precursors from IL23wt and IL23ko mice. After the BM 
engraftment, the animals were challenged s.c. with TRAMP-C1 cells. When tumors reached 
≈ 100 mm3, mice were surgically castrated and monitored for tumor progression. b, H&E, 
Ki-67 and pSTAT3Y705 immunohistochemical staining (Ki-67 and pSTAT3Y705 brown; 
nuclei, blue) of representative TRAMP-C1 IL23wt and TRAMP-C1 IL23ko bearing mice. 
Scale Bar 25 μM. c, Quantification of Ki-67 positive cells is reported as a percentage of 
total. TRAMP-C1 IL23wt (n=8) and TRAMP-C1 IL23ko (n=4), one tumor per mouse, mean 
of three sections per mouse, ≥ 3 fields per section. Biological mean ± SE. Statistical analyses 
(Unpaired two-sided t test): **P <0.01. d-e, PMN-MDSCs frequencies determined by flow 
cytometry in the tumor and in the spleen of TRAMP-C1 IL23wt (n=3) and TRAMP-C1 
IL23ko (n=3) bearing mice 10 days after castration. Data are reported as mean ± SE. f, 
Quantification of pSTAT3Y705 reported as a percentage of total. TRAMP-C1 IL23wt (n=8) 
and TRAMP-C1 IL23ko (n=4), one tumor per mouse, mean of three sections per mouse, ≥ 3 
fields per section. Statistical analyses (Unpaired two sided t test): ***P <0.001. g, Western 
blot for RORγ, pSTAT3Y705 and total STAT3 levels of prostate tumors of TRAMP-C1 
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IL23wt and TRAMP-C1 IL23ko bearing mice. Loading control: HSP90 antibody or total 
ERK antibody. The WB was validated al least two times. h, Quantification is reported as 
mean ± SEM of biological independent experiments: TRAMP-C1 IL23wt RORγ n=9; and 
TRAMP-C1 IL23ko RORγ n=9; TRAMP-C1 IL23wt pSTAT3Y705 n=4; and TRAMP-C1 
IL23ko pSTAT3Y705 n=3. Statistical analyses (Unpaired two sided t test): *P <0.05.
Extended Data 10. Pharmacological inhibition of IL23 in association with ADT delays disease 
progression in prostate cancer.
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a, H&E and Ki-67 immunohistochemical staining (Ki-67 brown; nuclei, blue) of 
representative castrated-Ptenpc-/- mice treated with αIL23, ENZA or both. Scale Bar 50 μM 
b, Quantification of Ki-67 reported as a percentage of total within the glands. One tumor per 
mouse, three sections per mouse, ≥ 3 fields per section. Mean ± SEM of a biological 
independent animals. Untreated n=6, αIL23 n=6, ENZA n=5 or both n=6. Statistical 
analyses (Unpaired two sided t test): **P <0.01; ***P <0.001. c, Upon castration, PMN-
MDSCs progressively infiltrate the tumor bed mainly recruited by CXCL5. Within the 
tumor, PMN-MDSCs start to produce higher amount of IL23, thus establishing a positive-
feedback loop that induce the over-expression of IL23R on the tumor epithelial cells and 
confer castration resistance by activating the STAT3/RORγ pathway. Enzalutamide 
treatment can block androgen receptor inducing sensitiveness of prostate cancer cells to 
androgen deprivation, but the persistent presence of PMN-MDSCs-derived IL23 rescues the 
drug sensitiveness leading to androgen deprivation resistance. Anti-IL23 treatment reverts 
castration resistance in prostate cancer enhancing the efficacy of enzalutamide.
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Figure 1. MDSCs infiltrate CRPC paralleling the activation of AR pathway and conferring 
castration resistance.
a, CD11b+ CD33+ CD15+ PMN-MDSCs within the tumors of CSPCs vs CRPCs. EpCAM 
yellow, CD15 green, CD33 red; CD11b pink; DAPI blue, n=51 biological independent 
patients per group reported as mean ± SEM. Statistical analyses (negative binomial 
regression model): P <0.001. b-d, Ptenpc-/- mice sham-operated (Sham) or surgically 
castrated (CTX) Ptenpc-/- mice at different time points. b, Tumor volume of the anterior 
prostate lobe. c, qRT-PCR analyses of the indicated genes in the prostate tumors at t=4 
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(castration sensitive phase; CS) and t=12 (castration resistance phase; CR). d, Flow 
cytometry for tumor PMN-MDSCs (gated on CD45+ cells). e, Percentages of tumor-
infiltrating immune cell populations (gated on CD45+ cells). f, Experimental scheme. g, 
TRAMP-C1 cell proliferation. h, Percentage of AnnexinV and 7AAD-negative TRAMP-C1 
cells. i, Percentage of AnnexinV and 7AAD-positive TRAMP-C1 cells. j, qRT-PCR analyses 
of the indicated genes in TRAMP-C1 cells. k, Experimental scheme. l, LNCaP cell 
proliferation. m, Volume of prostate tumors of CTX Ptenpc-/- mice treated or not with 
CXCR2 antagonist (αCXCR2) at completion of the study (12-weeks upon CTX). n, qRT-
PCR analyses of the indicated genes in the prostate tumors of mice treated as in m. Specific 
n values of biological independent animals (b, c, d, m, n) and independent samples (g-j, l) 
are shown and reported as mean ± SEM. b, d, h, i, -, l, m, Statistical analyses (Unpaired 
two-sided t-test): ns, not significant; *P <0.05; **P <0.01; ***P <0.001. b, d, Statistical 
analyses (One-way ANOVA, two-sided): P <0.001. c, g, j, n, Statistical analyses (Paired 
two-sided t-test): *P <0.05; **P <0.01; ***P <0.001.
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Figure 2. Tumor-infiltrating MDSCs produce IL23 that drives insensitivity to androgen 
deprivation.
a-c Prostate tumors from Ptenpc-/- mice Sham or CTX analyzed at t=12 a, Representative 
images of Ly6G+ IL23+ cells (nuclei, blue) and representative dot plot of Ly6G+ IL23+ cells 
gated on CD45+ cells in CTX mice. b-c, Representative histograms (left) and quantification 
(right; mean ± SE) showing b, Mean fluorescence intensity (MFI) of IL-23 within CD45+ 
CD11b+ Ly6G+ cells and c, MFI of IL-23R gated on CD45- EpCAM+ cells. b, c, n=3 
biological independent animals per group. d, Representative images of IL23, CD15, 
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EpCAM positive cells within the tumor of CRPC patients. a, d, Data were validated in at 
least three experiments. e, CD33+ IL23+ CD11b+ CD45+ cells within the tumor of CSPCs vs 
CRPCs (n=4 biological independent patients/cohort). f, IL23 levels in the plasma of CSPCs 
(n=20) and CRPCs (n=120) patients. g, Correlation analyses of the numbers of tumor-
infiltrating PMN-MDSCs and plasmatic IL23 levels in CRPC patients (n=28). Statistical 
analyses (negative binomial regression model) p <0.001. h-i, Tumor progression (t=days 
post-castration) of NSG™ TRAMP-C1 allografts treated with Isotype control (Untreated; 
n=4), anti-CSF1R antibody (αCSF1R; n=5) or αCXCR2 (n=5). h, Average tumor volume. i, 
Survival curves reported as Kaplan-Meier plot. Statistical analyses (Log rank (Mantel-Cox) 
test): **P <0.01. j, TRAMP-C1 cell proliferation. k, Percentage of AnnexinV and 7AAD-
negative TRAMP-C1 cells. l, Percentage of AnnexinV and 7AAD-positive TRAMP-C1 
cells. m, qRT-PCR analyses of the indicated genes in TRAMP-C1 cells. n, Cell proliferation 
of 3D cultures of reported organoids. rIL23 conditions were normalized to the None or 
F.A.D. condition respectively. e,f,h,j-n, Data are reported as mean ± SE. Specific n values of 
biological independent samples are shown in j-n. b, c, e, f, h, j-l, n, Statistical analyses 
(Unpaired two-sided t-test) and m, Statistical analyses (Paired two-sided t-test), *P <0.05; 
**P <0.01; ***P <0.001.
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Figure 3. IL23/IL23R axis regulates castration resistance in vivo and in vitro.
a, MRIs of representative Ptenpc-/-;IL23wt and Ptenpc-/-;IL23ko mice at the endpoint (upper 
panels). Waterfall plot depicting proportional change in tumor response for Ptenpc-/-;IL23wt 
(n=3) and Ptenpc-/-;IL23ko (n=3) mice. Mean ± SE. Statistical analyses (Unpaired two-sided 
t-test): *P <0.05, One-way ANOVA: P=0.0008. b, Representative H&E at the endpoint. 
Scale Bar 100 μM. Data are representative of at least three biological independent animals. 
c, Quantification of adenocarcinoma, prostatic intraepithelial neoplasia (PIN) or normal-like 
glands in Ptenpc-/-;IL23wt (n=3) and Ptenpc-/-;IL23ko (n=3) mice. d, Quantification of Ki-67+ 
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cells in Ptenpc-/-;IL23wt (n=4) and Ptenpc-/-;IL23ko (n=6). e, qRT-PCR analyses in the 
prostate tumors. f, g, Tumor volume and survival curves of TRAMP-C1 IL23wt and 
TRAMP-C1 IL23ko bearing mice. f, Statistical analyses (Unpaired two-sided t-test followed 
by Wilcoxon post-test): *P <0.05. h, qRT-PCR analyses in the tumors of TRAMP-C1 IL23wt 
or IL23ko bearing mice. i-j, NSG™ males challenged with TRAMP-C1 or TRAMP-C1-
IL23RKO cells, after CTX were treated with Isotype control (Untreated) or anti-IL23 
antibody (αIL23) and monitored for i, tumor progression and j, survival. WB for IL23R as 
insert (performed at least in double). g, j, Statistical analyses (Log rank (Mantel-Cox) test): 
**P <0.01; ***P <0.001. k, Quantification of pSTAT3Y705+ cells in Ptenpc-/-;IL23wt (n=4) 
and Ptenpc-/-;IL23ko mice (n=6). l-m WB and quantification for RORγ, pSTAT3Y705 and 
total STAT3 levels in prostate tumors. n, TRAMP-C1 cell proliferation o, qRT-PCR analyses 
in TRAMP-C1 cells. c, d, k, Data are reported as mean ± SE of one tumor per mouse (mean 
of three sections per mouse, ≥ 3 fields per section). e-i,j,k,m-o, Data are reported as mean ± 
SE. Specific n values of biological independent animals (i,j,k) and biological independent 
samples (m-o) are reported in figure. c, d, i, k, m, n, Statistical analyses (Unpaired two-
sided t-test), e, h, o, Statistical analyses (Paired two-sided t-test), *P <0.05; **P <0.01; ***P 
<0.001.
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Figure 4. IL23 inhibition improves enzalutamide efficacy in vivo.
a, CR Ptenpc-/- mice (12 weeks after castration) were randomly enrolled in the preclinical 
trial. Treatments: Isotype control (Untreated), anti-IL23 antibody (αIL23; 100ng/per mouse 
i.p. weekly), Enzalutamide (ENZA, 30 mg/kg/day administered daily by oral gavage on a 
Monday to Friday schedule) and Enzalutamide in combination with anti-IL23 antibody 
(ENZA+αIL23). b, Histological score. n=3 biological independent animals. Statistical 
analyses (Two-way ANOVA): p<0.001. c, Fold increase of the prostate anterior lobe volume 
(fold change compared with untreated group). d, Representative H&E and Ki-67 staining in 
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the tumors at completion of the study. Scale Bar 50 μM. e, qRT-PCR analyses of the 
indicated genes in the prostate tumors of CTX-Ptenpc-/- mice at completion of the preclinical 
trial. Statistical analyses (two-sided Paired t test): *P <0.05; ***P <0.001. f, Representative 
cleaved-Caspase3 staining in the tumors after one week of treatments. Scale Bar 50 μM. g, 
Quantification of cleaved-Casp 3 (percentage of total within the glands). d, f, Data are 
representative of at least in three biological independent animals. b, g, Data are reported as 
mean ± SEM of one tumor per mouse (mean of three sections per mouse, ≥ 3 fields per 
section). b,c,e,g Data are reported as mean ± SEM. Specific n values of biological 
independent animals are shown in c, e, g. c, g, Statistical analyses (Unpaired two-sided t-
test): ns, not significant; *P <0.05; **P <0.01; ***P <0.001.
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Table 1
Paired CSPC and CRPC biopsies (n=51)
CSPC biopsy
Age at diagnosis (years)
Mean, SD 61.2, 6.0
Staging (n)
T1 0
T2 3
T3 24
T4 10
NR 14
N0 9
N1 19
NR 23
M0 20
M1 22
NR 9
Biopsy site (n)
Prostate core 39
Prostatectomy 4
TURP 7
Lymph node 1
Histology (n)
Adenocarcinoma 51
Gleason (n)
8-10 34
7 13
≤6 2
NS 2
Presenting PSA (μg/L)*
Median, IQR 56, 18.4-152.5
Initial therapy (n)
Radical 21
Palliative 30
CRPC biopsy
Site of metastatic biopsy (n)
Bone marrow trephine 12
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Paired CSPC and CRPC biopsies (n=51)
Lymph node 30
Liver 3
TURP 3
Soft tissue 3
Treatments for CRPC at biopsy (n)
Docetaxel& 44
Cabazitaxel 21
Abiraterone^ 36
Enzalutamide 22
*6 values not available; 1 PSA was >1000 μg/L and calculated as 1000 μg/L
&3 patients received docetaxel for CSPC
^2 patients received abiraterone for CSPC
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